Get the Stockscreener App
1.20
6.19%
0.07
Pre-market:
1.19
-0.01
-0.83%
Pacific Biosciences Of California Inc stock is traded at $1.20, with a volume of 10.19M.
It is up +6.19% in the last 24 hours and up +0.00% over the past month.
Pacific Biosciences of California Inc is a biotechnology company focused on designing, developing, and manufacturing sequencing solutions that enable scientists and clinical researchers to improve their understanding of the genome and ultimately, resolve genetically complex problems. It operates in, one reportable segment: the development, manufacturing, and marketing of an integrated platform for genetic analysis. The majority of the company's revenue is derived from Americas, followed by Asia-Pacific and Europe Middle East, and Africa.
See More
Previous Close:
$1.13
Open:
$1.15
24h Volume:
10.19M
Relative Volume:
1.02
Market Cap:
$328.64M
Revenue:
$188.87M
Net Income/Loss:
$-400.38M
P/E Ratio:
-0.80
EPS:
-1.5
Net Cash Flow:
$-260.90M
1W Performance:
+8.11%
1M Performance:
+0.00%
6M Performance:
-47.83%
1Y Performance:
-28.57%
1-Day Range:
$1.13
$1.23
1-Week Range:
$1.08
$1.23
52-Week Range:
$1.06
$2.72
Pacific Biosciences Of California Inc Stock (PACB) Company Profile
Name
Pacific Biosciences Of California Inc
Sector
Industry
Phone
650-521-8000
Address
1305 O'BRIEN DRIVE, MENLO PARK, CA
Compare PACB with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PACB
Pacific Biosciences Of California Inc
|
1.20 | 328.64M | 188.87M | -400.38M | -260.90M | -1.50 |
|
ABT
Abbott Laboratories
|
134.00 | 227.71B | 42.34B | 13.50B | 6.66B | 7.71 |
|
BSX
Boston Scientific Corp
|
103.29 | 152.66B | 17.55B | 2.03B | 2.72B | 1.37 |
|
SYK
Stryker Corp
|
382.46 | 142.93B | 23.22B | 2.86B | 3.58B | 7.40 |
|
MDT
Medtronic Plc
|
83.62 | 107.17B | 33.20B | 4.26B | 5.47B | 3.29 |
|
EW
Edwards Lifesciences Corp
|
74.63 | 44.04B | 5.54B | 4.18B | 623.10M | 7.00 |
Pacific Biosciences Of California Inc Stock (PACB) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-11-24 | Downgrade | UBS | Buy → Neutral |
| Jun-03-24 | Resumed | Jefferies | Buy |
| Apr-22-24 | Downgrade | JP Morgan | Overweight → Neutral |
| Apr-18-24 | Downgrade | Goldman | Buy → Neutral |
| Dec-14-23 | Initiated | Guggenheim | Neutral |
| Dec-14-23 | Initiated | Stephens | Overweight |
| Dec-13-23 | Initiated | Wolfe Research | Peer Perform |
| Nov-17-23 | Upgrade | UBS | Neutral → Buy |
| Oct-31-23 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Sep-28-23 | Initiated | Bernstein | Outperform |
| Jul-05-23 | Resumed | JP Morgan | Overweight |
| Jun-30-23 | Initiated | Goldman | Buy |
| May-10-23 | Initiated | Barclays | Equal Weight |
| Mar-31-23 | Upgrade | TD Cowen | Market Perform → Outperform |
| Feb-02-23 | Initiated | UBS | Neutral |
| Jan-20-23 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Jan-05-23 | Initiated | Scotiabank | Sector Outperform |
| Jan-21-22 | Resumed | Cantor Fitzgerald | Overweight |
| Jan-06-22 | Resumed | Piper Sandler | Neutral |
| Oct-15-21 | Resumed | Cowen | Market Perform |
| Sep-27-21 | Initiated | Canaccord Genuity | Buy |
| Feb-11-21 | Upgrade | Piper Sandler | Neutral → Overweight |
| Nov-03-20 | Downgrade | Piper Sandler | Overweight → Neutral |
| Oct-02-20 | Upgrade | JP Morgan | Neutral → Overweight |
| Sep-09-20 | Initiated | Morgan Stanley | Equal-Weight |
| Jun-02-20 | Resumed | Cantor Fitzgerald | Overweight |
| Mar-09-20 | Resumed | Cantor Fitzgerald | Overweight |
| Oct-15-19 | Upgrade | Piper Jaffray | Neutral → Overweight |
| Apr-02-19 | Downgrade | Stephens | Overweight → Equal-Weight |
| Oct-19-18 | Initiated | Cowen | Outperform |
| Nov-03-17 | Downgrade | First Analysis Sec | Overweight → Equal-Weight |
| Sep-28-17 | Downgrade | CL King | Buy → Neutral |
| Nov-03-16 | Reiterated | Cantor Fitzgerald | Buy |
| Jun-27-16 | Initiated | CL King | Buy |
| Apr-15-16 | Initiated | First Analysis Sec | Overweight |
| Feb-04-16 | Downgrade | Piper Jaffray | Overweight → Neutral |
| Jan-04-16 | Reiterated | Cantor Fitzgerald | Buy |
| Oct-23-15 | Upgrade | Piper Jaffray | Neutral → Overweight |
| Aug-27-15 | Initiated | Cantor Fitzgerald | Buy |
| Feb-04-15 | Reiterated | Maxim Group | Buy |
| Sep-26-13 | Reiterated | Maxim Group | Buy |
| Jan-14-13 | Reiterated | Maxim Group | Buy |
View All
Pacific Biosciences Of California Inc Stock (PACB) Latest News
Pacific Biosciences: Q1 Earnings Snapshot - Huron Daily Tribune
Pacific Biosciences (PACB) Reports Q1 Earnings: What Key Metrics Have to Say - Nasdaq
Pacific Biosciences (PACB) Reports Q1 2025 Financials Amid Macroeconomic Challenges - GuruFocus
PacBio (NASDAQ:PACB) Beats Expectations in Strong Q1 - Yahoo Finance
PacBio Q1 2025 slides: Consumable growth offsets instrument revenue decline - Investing.com Canada
Pacific Biosciences of California (PACB) Reports Q1 Loss, Tops Revenue Estimates - Yahoo Finance
PacBio Announces First Quarter 2025 Financial Results - Stock Titan
PacBio (PACB) Sees Increased Options Activity Ahead of Earnings | PACB Stock News - GuruFocus
Digital Genome Market Forecast: Growth Trends, Key Players & - openPR.com
Pacific Biosciences (PACB) Prepares for Q1 Earnings Announcement - GuruFocus
Earnings To Watch: Pacific Biosciences of California Inc (PACB) Reports Q1 2025 Result - GuruFocus
PacBio (PACB) Q1 Earnings: What To Expect - Yahoo Finance
Pacific Biosciences of California Inc expected to post a loss of 19 cents a shareEarnings Preview - TradingView
PacBio (PACB) Launches Pioneering Genomic Project in Asia Pacific | PACB Stock News - GuruFocus
Press Release Distribution & PR Platform - ACCESS Newswire
PacBio (PACB) Q4 Earnings Report Preview: What To Look For - Barchart.com
Pacific Biosciences of California (PACB) Stock Falls Amid Market Uptick: What Investors Need to Know - Yahoo Finance
Pacific Biosciences Says New Technology to Enhance HiFi Sequencing - marketscreener.com
PacBio Licenses CUHK AI Tech To Boost 5-Base Methylation Detection In HiFi Sequencing - Nasdaq
PacBio (PACB) Enhances Methylation Detection in HiFi Sequencing - GuruFocus
PacBio Licenses Advanced DNA Methylation Detection Technology to Enhance HiFi Sequencing Accuracy - Nasdaq
PACB stock touches 52-week low at $1.08 amid market challenges - Investing.com Australia
Pacific Biosciences of California (PACB) Flat As Market Gains: What You Should Know - Yahoo Finance
Pacific Biosciences of California Selected by Davos Alzheimer's Collaborative as Technology Partner - marketscreener.com
PacBio partners with global Alzheimer’s initiative By Investing.com - Investing.com India
PacBio partners with global Alzheimer’s initiative - Investing.com Australia
PacBio (PACB) Joins DAC's North African Dementia Project | PACB Stock News - GuruFocus
PacBio Partners with Davos Alzheimer’s Collaborative to Advance Alzheimer's Research in North Africa - Nasdaq
Selling Pacific Biosciences of California Shares at a Lower Price Than Current Market Value May Have Been a Costly Mistake for Insiders - simplywall.st
PacBio (PACB) Price Target Cut Amid Sector Funding Concerns | PA - GuruFocus
Positive week for Pacific Biosciences of California, Inc. (NASDAQ:PACB) institutional investors who lost 57% over the past year - Yahoo
Pacific Biosciences of California jumps 22% after prelim Q1 results, guides FY - MSN
Canaccord maintains $3 price target on PACB, reiterates Buy By Investing.com - Investing.com South Africa
Tariffs, NIH ‘uncertainty’ force PacBio into layoffsSan Francisco Business Times - The Business Journals
Canaccord maintains $3 price target on PACB, reiterates Buy - Investing.com
PacBio outlines cost-cutting, revenue meets Q1 target By Investing.com - Investing.com South Africa
PacBio to cut jobs, lower spending over NIH funding cuts and tariffs - Reuters
Healthcare Stocks Ride a Tariffs-Relief Wave -- Healthcare Roundup - marketscreener.com
PacBio (PACB) and Hims & Hers Health (HIMS), 10x Genomics (TXG), Moderna (MRNA) Shares Are Soaring, What You Need To Know - The Globe and Mail
Sequencing Company PacBio Cuts Costs Amid Uncertainty Around NIH Funding And New Tariffs - Benzinga
Simply Good Foods, Pacific Biosciences of California, Kura Sushi, Delta Air Lines And Other Big Stocks Moving Higher On WednesdayAkso Health (NASDAQ:AHG), Anglogold Ashanti (NYSE:AU) - Benzinga
Pacific Biosciences of California Sees Lower Q1 Revenue, Plans Job Cuts to Reduce Costs - MarketScreener
PacBio Q1 Prel. Revenue Down, Says Met Expectations; To Cut Jobs - Nasdaq
PacBio outlines cost-cutting, revenue meets Q1 target - Investing.com
Pacbio posts Preliminary Q1 2025 Revenue And Reiterates 2025 Revenue Guidance - marketscreener.com
Pacific Biosciences of California, Inc. Reiterates Earnings Guidance for the Full Year 2025 - marketscreener.com
PacBio's Bold Move: $50M Cost Cut Plan as Q1 Shows Record Consumables Growth - Stock Titan
PacBio to cut headcount, costs in face of tariff headwinds - Fierce Biotech
PacBio Strengthens Leadership: New CFO Joins with Strategic Equity Package - Stock Titan
Customer success story: The University of Bern takes long-read sequencing to the next level with SPRQ chemistry - PacBio
Pacific Biosciences of California appoints CFO - MSN
Pacific Biosciences Of California Inc Stock (PACB) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.04%
0.55%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):